Últimas noticias sobre Bio-Path Hldgs (NASDAQ:BPTH) Bolsa

Bio-Path Hldgs

Bio-Path Holdings

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Bio-Path Holdings Inc

Clinical Program Overview
<ul>
<li>Bio-Path's clinical development program consists of one Phase 2 clinical trial, two Phase 1 or 1/1b clinical trials, and two preclinical programs. Bio-Path has developed a molecular biomarker package for its Phase 2 clinical trial in acute myeloid leukemia (AML) that was developed to identify patients that potentially have a higher propensity to respond to prexigebersen treatment. Bio-Path expects to utilize the biomarker package to accompany prexigebersen treatment in 2025 and expects to evaluate prexigebersen for the treatment of obesity. In addition, BP1001-A is in preclinical development for treatment of obesity in Type 2 Diabetes patients, which may be submitted to the U.S. Food and Drug Administration (FDA) later in the year in an Investigational New Drug (IND) application.&nbsp;&nbsp;</li>
<li>Development of Molecular Biomarkers – Bio-Path has developed a molecular biomarker package to accompany prexigebersen treatment, the goal of which is to identify patients with a genetic profile more likely to respond to treatment thereby improving probability of success for this program. The emerging role of biomarkers has been enhancing cancer development over the past decade and has become a more common companion to many cancer development programs. Bio-Path expects to utilize the prexigebersen biomarkers in 2025 in the Phase 2 AML clinical trial and to develop additional molecular biomarker packages to accompany its new programs.</li>
<li>Prexigebersen Phase 2 Clinical Trial – Bio-Path's Phase 2 clinical trial for the treatment of AML is comprised of three cohorts of patients and treatments, each separately approvable by the FDA as a new indication. The first two cohorts are treating patients with the triple combination of prexigebersen, decitabine and venetoclax. The first cohort includes untreated AML patients, and the second cohort includes relapsed/refractory AML patients. Finally, the third cohort is treating relapsed/refractory AML patients who are venetoclax-resistant or intolerant with the two-drug combination of prexigebersen and decitabine. Outcomes for these older patients who are unable to receive intensive chemotherapy due to the challenging side effect profile, remain suboptimal with a median survival of only 5 to 10 months. Bio-Path also expects to utilize an advisory panel of AML experts to assist in the design of the final clinical development plans through potential FDA approval. Other significant milestones expected during 2025 include the completion of Cohort 2 and an interim analysis for Cohort 3.</li>
<li>Phase 1/1b Clinical Trial in BP1001-A in Advanced Solid Tumors – A Phase 1/1b clinical trial of BP1001-A in patients with advanced or recurrent solid tumors, including ovarian and uterine, pancreatic and breast cancer, is ongoing. BP1001-A is a modified product candidate that incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties. The Phase 1 study has advanced to the second, higher dose level and the first patient in the second dose cohort continued experiencing a positive response which may signal that this analog of prexigebersen has potential as a new treatment for advanced solid tumors. The patient continues to be doing well after ten months on study after failing extensive chemotherapy and surgical treatment for gynecologic cancer, demonstrating a 15% reduction in her primary tumor through nine cycles of treatment. Moreover, it appears that these positive outcomes may have contributed to allowing her to continue with rigorous exercise and improved quality of life. Completion of the second and third dosing cohorts are expected in 2025.</li>
<li>The Phase 1b portion of the study is expected to commence after successful completion of the three BP1001-A monotherapy dose level cohorts and is intended to assess the safety and efficacy of BP1001-A in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors. Phase 1b studies are also expected to be initiated in combination with gemcitabine in Stage 4 pancreatic cancer and combination therapy in breast cancer.</li>
<li>Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML – A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Venetoclax treats AML patients by blocking the activity of the Bcl-2 protein in AML patients. However, over time patients become resistant to venetoclax. BP1002 treats the Bcl-2 target by blocking the cell's ability to produce Bcl-2 and could provide benefit for these venetoclax resistant patients. AML patients that fail frontline venetoclax-based therapy have very poor prognosis with median overall survival of less than three months. The first dose cohort consisted of a starting dose of 20 mg/m2, the second dose cohort of 40 mg/m2 and there were no dose limiting toxicities. The third dosing cohort of 60 mg/m2 is open and enrollment closed faster than expected which Bio-Path believes reflects the need for additional treatment options.</li>
<li>Prexigebersen as Potential Treatment for Obesity in Type 2 Diabetes Patients – BP1001-A downregulates Grb2 expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggeststhat by downregulating Grb2 expression, BP1001-A&nbsp;could help lower blood glucose levels by affecting insulin signaling. Bio-Path conducted preclinical studies that confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes. In 2025, Bio-Path expects to complete preclinical testing and to file an IND.</li>
</ul>

Biotech

News

Health Care

General

BPTH

Bio-path Provides A Clinical Development And Operational Update For 2025

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 376.8% to $3.19 during Thursday's pre-market session. The market value of their outstanding shares is at $13.7 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock rose 50.2% to $18.4. The company's market cap stands at $2.0 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 38.56% to $2.12. The market value of their outstanding shares is at $1.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 35.45% to $1.49. The market value of their outstanding shares is at $76.7 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock rose 33.78% to $9.98. The company's market cap stands at $578.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock rose 26.21% to $4.77. The market value of their outstanding shares is at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 35.1% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 26.75% to $2.41. The market value of their outstanding shares is at $10.1 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock fell 20.01% to $11.2. The company's market cap stands at $681.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 17.87% to $3.31. The market value of their outstanding shares is at $29.5 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 13.93% to $3.4. The market value of their outstanding shares is at $3.2 million. </li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock fell 12.85% to $390.0. The market value of their outstanding shares is at $100.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEMD

ISPC

MESO

MRKR

MYNZ

OMER

PLRX

PLRZ

VRTX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Thursday.
The Dow traded up 0.55% to 42,557.62 while the NASDAQ rose 0.52% to 19,492.93. The S&amp;P 500 also rose, gaining, 0.46% to 5,899.14.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Utilities shares rose by 1.3% on Thursday.
In trading on Thursday, energy shares fell by 0.8%.
Top Headline
U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares shot up 39% to $10.38 after the company's Narsoplimab met pivotal trial primary endpoint.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 100% to $1.6500 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 162% to $1.7501 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 63% to $0.3101 as the company reported the pricing of public offering.</li>
<li>Shares of Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) were down 23% to $60.49 after the company reported worse-than-expected Q2 earnings and lowered FY25 outlook.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down, falling 17% to $86.66. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $69.89 while gold traded down 1.5% at $2,614.90.
Silver traded down 4% to $29.540 on Thursday, while copper fell 1.8% to $4.0835.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 dipped 1.51%, Germany's DAX fell 1.35% and France's CAC 40 declined 1.22%. Spain's IBEX 35 Index fell 1.53%, while London's FTSE 100 fell 1.14%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
<li>The Kansas City Fed's Manufacturing Production Index declined by one point to a reading of -5 in December.</li>
<li>U.S. natural-gas supplies fell 125 billion cubic feet during the week ending Dec. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Equities

Eurozone

Commodities

Markets

Trading Ideas

LITM

TPET

Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline

Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here&#8217;s <a href="https://www.benzinga.com/quote/BPTH/news">what you need to know.</a>
What To Know: The preclinical studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating the growth factor receptor-bound protein 2. These findings suggest BP1001-A could improve insulin-induced metabolic processes and offer a new therapeutic option for obesity-related metabolic conditions.
Following these findings, the company began animal studies to validate the efficacy of BP1001-A. Pending success, the company plans on holding a first-in-human Phase 1 clinical trial in 2025 to assess safety, pharmacokinetics, and dosing.
BPTH Price Action: Bio-Path Holdings shares were up 104.8% at $1.37 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19112954/BPTH-1024x538.png" alt="" class="wp-image-700143" style="width:434px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19112954/BPTH-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19112954/BPTH-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19112954/BPTH-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19112954/BPTH.png 1153w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/12/42597180/even-in-2023-charlie-munger-said-elon-musk-overestimates-himself-but-credited-his-success-to-one-key-factor">Even in 2023, Charlie Munger Said &#8216;Elon Musk Overestimates Himself&#8217; But Credited His Success to One Key Factor</a></li>
</ul>
Image Via Shutterstock.

Bio-Path Holdings Shares Were On The Rise: What's Going On?

U.S. stocks traded higher midway through trading, with the S&amp;P 500 gaining around 0.4% on Thursday.
The Dow traded up 0.39% to 42,493.51 while the NASDAQ rose 0.39% to 19,468.70. The S&amp;P 500 also rose, gaining, 0.38% to 5,894.42.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Utilities shares rose by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 0.9%.
Top Headline
The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares shot up 50% to $11.22 after the company's Narsoplimab met pivotal trial primary endpoint.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 180% to $2.30 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 135% to $1.5700 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 59% to $0.3313 as the company reported the pricing of public offering.</li>
<li>Shares of Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) were down 23% to $60.43 after the company reported worse-than-expected Q2 earnings and lowered FY25 outlook.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down, falling 17% to $86.16. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $70.10 while gold traded down 1.7% at $2,608.00.
Silver traded down 4.8% to $29.275 on Thursday, while copper fell 2% to $4.0760.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.51%, Germany's DAX fell 1.35% and France's CAC 40 declined 1.22%. Spain's IBEX 35 Index fell 1.53%, while London's FTSE 100 fell 1.14%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
<li>The Kansas City Fed's Manufacturing Production Index declined by one point to a reading of -5 in December.</li>
<li>U.S. natural-gas supplies fell 125 billion cubic feet during the week ending Dec. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Intraday Update

Gold Falls Sharply, Lamb Weston Shares Plunge

Bio-Path Shares Halted On Circuit Breaker, Stock Now Up 278.2%

Bio-Path Holdings Shares Resume

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.47% to 42,525.10 while the NASDAQ rose 0.84% to 19,554.71. The S&amp;P 500 also rose, gaining, 0.62% to 5,908.52.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 0.7%.
Top Headline
Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) posted better-than-expected earnings for its first quarter, while sales missed expectations.
The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares shot up 532% to $13.85.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 358% to $3.7550 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 281% to $2.55 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 61% to $0.3185 as the company reported the pricing of public offering.</li>
<li>Shares of Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) were down 38% to $0.4070.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 43% to $1.15.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $70.78 while gold traded down 1.7% at $2,607.90.
Silver traded down 4.6% to $29.315 on Thursday, while copper fell 1.5% to $4.0955.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.7%, Germany's DAX fell 1.3% and France's CAC 40 declined 1.3%. Spain's IBEX 35 Index fell 1.7%, while London's FTSE 100 fell 1.3%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

PRFX

WLGS

US Stocks Higher, Micron Reports Downbeat Sales

Bio-Path Holdings Shares Resume Trade

Bio-Path Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Up 341%

Bio-Path Shares Halted On Circuit Breaker

BP1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggeststhat by downregulating Grb2 expression, BP1001-A&nbsp;could help lower blood glucose level by affecting insulin signaling. Bio-Path conducted preclinical studies that confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes.&nbsp;&nbsp; The study results showed:
<ul>
<li>BP1001-A reduced Grb2 protein expression in myoblast cells</li>
<li>BP1001-A increased the levels of phosphorylated AKT and phosphorylated FOXO-1 in myoblast and hepatoma cells in the presence of insulin</li>
</ul>
These initial data confirmed that by downregulating Grb2 expression, BP1001-A could enhance insulin-induced metabolic events by affecting the insulin/phosphoinositol-3 kinase (PI3K)/AKT pathway and increase insulin sensitivity.&nbsp;

Bio-Path Reported That Results From Preclinical Studies Of BP1001-A For Obesity Demonstrated Enhanced Insulin Sensitivity, Confirming BP1001-A As A Potential Treatment For Obesity And Related Metabolic Diseases In Type 2 Diabetes Patients

WIIM

Bio-Path Holdings shares are trading higher after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 172.2% to $12.55 during Wednesday's pre-market session. The company's market cap stands at $407.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock rose 34.75% to $0.53. The company's market cap stands at $5.3 million. </li>
<li>Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) stock moved upwards by 34.18% to $31.01. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q2 earnings report came out 4 days ago. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) stock increased by 17.3% to $1.7. The market value of their outstanding shares is at $19.8 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 14.86% to $0.85. The company's market cap stands at $3.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares moved upwards by 14.71% to $2.65. The market value of their outstanding shares is at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares declined by 67.0% to $8.05 during Wednesday's pre-market session. The market value of their outstanding shares is at $98.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares decreased by 66.41% to $0.43. The company's market cap stands at $17.7 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares declined by 36.51% to $14.66. The market value of their outstanding shares is at $446.0 million. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares declined by 33.88% to $0.2. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 28.24% to $3.33. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock fell 26.93% to $0.46. The market value of their outstanding shares is at $3.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

CADL

CLRB

HEPA

IBRX

MBRX

NIVF

PDCO

QTTB

SYBX

TFFP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Bio-Path shares are trading higher after the company outlined growing evidence that supports the development of BP1001-A for the treatment for obestity and related metabolic disease in type 2 diabetes patients.

Bio-Path Holdings Outlined The Growing Body Of Scientific Evidence That Bio-path Believes Supports The Development Of BP1001-A For The Treatment For Obesity And Related Metabolic Diseases In Type 2 Diabetes Patients

Bio-Path Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.01) by 30.69 percent.

Earnings

Bio-Path Holdings Q3 2024 GAAP EPS $(0.70) Beats $(1.01) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $72.08 million. 
• Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) is projected to report quarterly loss at $0.54 per share on revenue of $16.50 million. 
• Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) is projected to report quarterly loss at $0.13 per share on revenue of $9.90 million. 
• Aegon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEG#NYSE">AEG</a>) is projected to report earnings for its third quarter. 
• Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is expected to report earnings for its third quarter. 
• WiSA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) is likely to report quarterly loss at $0.68 per share on revenue of $1.00 million. 
• AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is likely to report quarterly loss at $0.10 per share on revenue of $20 thousand. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $87.84 million. 
• RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $105.08 million. 
• Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is projected to report quarterly earnings at $2.10 per share on revenue of $33.95 billion. 
• Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $746.54 million. 
<h3>Companies Reporting After The Bell</h3>
• Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) is likely to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BABA

DGHI

NEXN

NGNE

SGML

TRIB

WISA

Earnings Scheduled For November 15, 2024

Bio-Path Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-15. Here's what investors need to know before the announcement.
Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-1.02. 
Anticipation surrounds Bio-Path Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.38, leading to a 1.32% drop in the share price on the subsequent day.
Here's a look at Bio-Path Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.54</td>
<td>-4.80</td>
<td>-5.40</td>
<td>-6.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.16</td>
<td>-4.88</td>
<td>-4.23</td>
<td>-6.4</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-13.0%</td>
<td>-6.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731592867_0.png" alt="eps graph" />
<h3>Market Performance of Bio-Path Holdings's Stock</h3>
Shares of Bio-Path Holdings were trading at $0.884 as of November 13. Over the last 52-week period, shares are down 91.66%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BPTH/earnings">To track all earnings releases for Bio-Path Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Bio-Path Holdings's Earnings Preview

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares increased by 51.2% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock rose 23.64% to $1.83. The company's market cap stands at $136.7 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 21.54% to $0.9. The company's market cap stands at $65.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 18.47% to $1.09. The market value of their outstanding shares is at $1.7 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock increased by 10.83% to $0.44. The market value of their outstanding shares is at $6.1 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock rose 10.28% to $0.35. The market value of their outstanding shares is at $26.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 11.8% to $0.6 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 11.53% to $0.23. The market value of their outstanding shares is at $1.4 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $2.7 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares declined by 9.44% to $1.11. The company's market cap stands at $67.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 9.31% to $0.58. The market value of their outstanding shares is at $5.8 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock decreased by 7.2% to $2.41. The company's market cap stands at $5.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLSD

CTCX

TIVC

WINT

XCUR

Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript

Goldman Sachs sees more China tariffs in early 2025 with Trump set to return

Bio-Path Holdings ( ($BPTH) ) has released its Q3 earnings. Here is a breakdown of the information Bio-Path Holdings presented to its investors. Bi...

Bio-Path Holdings Expands DNAbilize® Technology Applications

Warning: BPTH is at high risk of performing badly

Bio-Path (BPTH) outlined the growing body of scientific evidence that Bio-Path believes supports the development of BP1001-A for the treatment for ...

Bio-Path outlines rationale for development of BP1001-A

Bio-Path Holdings ( ($BPTH) ) just unveiled an announcement. Bio-Path Holdings announced its strategic focus on the development of BP1001-A as a po...

Bio-Path Holdings Shifts Focus to Metabolic Program

An announcement from Bio-Path Holdings ( ($BPTH) ) is now available. Bio-Path Holdings, Inc. has been notified by Nasdaq that its common stock has ...

Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes

Bio-Path (BPTH) reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001...

Bio-Path announces preclinical testing of BP1001-A

Bio-Path Holdings ( ($BPTH) ) has provided an announcement. Bio-Path Holdings has announced successful preclinical testing of BP1001-A, showing enh...

Bio-Path Holdings: Promising Preclinical Results for BP1001-A

Bio-Path Holdings ( ($BPTH) ) has issued an announcement. Bio-Path Holdings announced significant advancements in its clinical development pipeline...

Bio-Path Holdings Advances Clinical Pipeline for 2025

ASHR

CHIQ

CNYA

CQQQ

CWEB

CXSE

KLIP

KWEB

MCHI

YANG

YINN

ACHR, BPTH, PLUG, REGRF:

Press Releases

"Peraso Inc. (NASDAQ: PSRO) Pioneers mmWave Technology: The Next-Generation Wireless Communications" see bonus stocks inside…..

Financing

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Analyst Ratings

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Early Santa Claus Rally Highlights Power Nickel Inc. (TSXV: PNPN) and Other Stocks to Watch Now!

Comments

Bio-Path Hldgs

Noticias

Últimas noticias sobre Bio-Path Hldgs (NASDAQ:BPTH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL